Deerfield Management Company »

Allogene Therapeutics shares owned by Deerfield Management Company

Quarter-by-quarter ownership of Allogene Therapeutics (ALLO) shares owned by Deerfield Management Company from 13F filings

Historical chart of Deerfield Management Company investment in Allogene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Allogene Therapeutics held by Deerfield Management Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allogene Therapeutics by Deerfield Management Company

Quarter filed Position value Share count Share price at filing
2023-12-31 $90k 28k 3.21
2019-03-31 $9.4M 327k 28.91
2018-12-31 $8.8M 327k 26.93

More positions owned by Deerfield Management Company

Nuvalent Inc-a (NUVL)
Glaukos Corp Note 2.750% 6/1 (Principal)
Viatris (VTRS)
Invitae Corp Debt 4.500% 3/1 (Principal)
Natera Note 2.250% 5/0 (Principal)
Catalyst Pharmaceutical Partners (CPRX)
Centene Corporation (CNC)
Brookdale Sr Living Note 2.000%10/1 (Principal)
Insmed Note 1.750% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Accolade Note 0.500% 4/0 (Principal)
Oscar Health Cl A (OSCR)
Owens & Minor (OMI)
Adapthealth Corp Common Stock (AHCO)
Springworks Therapeutics (SWTX)

View all positions for Deerfield Management Company

Top funds holding Allogene Therapeutics

Tpg Gp A
Vanguard Group
Jpmorgan Chase & Co
PRIMECAP Management Company
Citadel Advisors
Goldman Sachs Group
T. Rowe Price Associates
Two Sigma Investments
Millennium Management
Vida Ventures Advisors
Dimensional Fund Advisors
Two Sigma Advisers
Charles Schwab Investment Management
Caxton Associates
Nordea Investment Management Ab

View all funds holding Allogene Therapeutics